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Background: Medication Guides consisting of crucial interactions and side effects are extensive and complex. Due to the
exhaustive information, patients do not retain the necessary medication information, which can result in hospitalizations and
medication nonadherence. A gap exists in understanding patients’ cognition of managing complex medication information.
However, advancements in technology and artificial intelligence (AI) allow us to understand patient cognitive processes to design
an app to better provide important medication information to patients.
Objective: Our objective is to improve the design of an innovative AI- and human factor–based interface that supports patients’
medication information comprehension that could potentially improve medication adherence.
Methods: This study has three aims. Aim 1 has three phases: (1) an observational study to understand patient perception of fear
and biases regarding medication information, (2) an eye-tracking study to understand the attention locus for medication information,
and (3) a psychological refractory period (PRP) paradigm study to understand functionalities. Observational data will be collected,
such as audio and video recordings, gaze mapping, and time from PRP. A total of 50 patients, aged 18-65 years, who started at
least one new medication, for which we developed visualization information, and who have a cognitive status of 34 during
cognitive screening using the TICS-M test and health literacy level will be included in this aim of the study. In Aim 2, we will
iteratively design and evaluate an AI-powered medication information visualization interface as a smartphone app with the
knowledge gained from each component of Aim 1. The interface will be assessed through two usability surveys. A total of 300
patients, aged 18-65 years, with diabetes, cardiovascular diseases, or mental health disorders, will be recruited for the surveys.
Data from the surveys will be analyzed through exploratory factor analysis. In Aim 3, in order to test the prototype, there will be
a two-arm study design. This aim will include 900 patients, aged 18-65 years, with internet access, without any cognitive
impairment, and with at least two medications. Patients will be sequentially randomized. Three surveys will be used to assess the
primary outcome of medication information comprehension and the secondary outcome of medication adherence at 12 weeks.
Results: Preliminary data collection will be conducted in 2021, and results are expected to be published in 2022.
Conclusions: This study will lead the future of AI-based, innovative, digital interface design and aid in improving medication
comprehension, which may improve medication adherence. The results from this study will also open up future research
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opportunities in understanding how patients manage complex medication information and will inform the format and design for
innovative, AI-powered digital interfaces for Medication Guides.
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For decades, the US Food and Drug Administration (FDA) and
drug manufacturers provided detailed Medication Guides to the
public to effectively communicate crucial patient safety [1].
The guides include warnings, precautions, and other lists of
adverse drug reactions [2]. Unfortunately, the information
presented in these Medication Guides often contains complicated
medical jargon. As a result, the information is difficult to read,
especially among patients with lower literacy skills [3]. One
study found that only about half of the participants understood
the information presented [4]. In another exploratory study,
researchers used a mixed methods approach that combines
eye-tracking technology, a survey, and qualitative data to
explore self-reported measures of drug-risk reading and actual
information recall. More than 80% of participants (n=29)
claimed to have read or comprehended only half or more of the
risk information. However, eye-tracking measures revealed
limited to no understanding of risks and minimal unaided recall
[5].
Consequently, patients cannot identify pivotal warnings from
the guides, as evidenced by an increase in all medication-related
hospitalizations by 117% from 1997 to 2008 [6]. Limited
research in this area suggests that minimal patient engagement
with information may contribute to unrecognized adverse effects
that can lead to poor adherence. Furthermore, patient cognition
and low literacy levels have a negative impact on medication
adherence [7-9]. Therefore, the solution may not be whether or
not the information was presented but rather how the information
presented supports the cognition of the patient [10]. Moreover,
understanding the patient’s cognitive processes could ultimately
impact both intentional and unintentional medication
nonadherence. Intentional nonadherence relates to stopping or
altering prescribed medications through a perceived purpose,
whereas unintentional medication nonadherence relates to
specific circumstances that impede compliance, including
forgetting to take a dose [11]. Both intentional and unintentional
nonadherence lead to poor outcomes and uncontrolled disease
states. Additionally, studies have detected a relationship between
nonadherence and health literacy [12,13]. One study in particular
investigated asthmatic patient perspectives of medication
nonadherence to inhaled corticosteroids and observed that a
factor for noncompliance was suboptimal knowledge of
medications [14]. Moreover, health literacy is positively
associated with cognition [15]. Thus, patients with lower health
literacy and lower cognition have more serious adverse drug
events [16]. By understanding cognition, novel solutions to
medication nonadherence can potentially be developed. Previous
studies in understanding cognitive processes mainly focused
on the decision making of clinicians to support cognition
[17-19]. Research on the aspects of understanding the patient’s
cognition is still limited. Thus, a gap exists in the understanding
of how patients manage complex medication information
cognitively in the digital environment.
Currently, the patient’s cognition can be supported through
effective medication information communication using digital
platforms, such as smartphone apps. In particular, recent
advancements in artificial intelligence (AI) embedded into
smartphone apps have the potential for a significant impact to
monitor and eventually comprehend different features of the
patient's cognition [20,21].
We hypothesize that interactive information visualization using
human factors design principles delivered through a smartphone
platform has the potential to improve medication information
retention. Infographics or interactive visualizations using
pictures and illustrations have been effective for complex
information communication and have proven the age-old saying
“a picture is worth a thousand words” [22-25]. Furthermore,
AI-based smartphone devices have proven to be effective in
clinical trials and chronic disease management to improve
medication adherence [21,26]. Utilizing advanced machine
learning algorithms, smartphone apps have the potential to
improve medication information delivery to patients.
Specifically, algorithms based on AI can help advance our
understanding of patients’ cognitive processes and provide
solutions through digital health technology.
Objective
Our goal is to improve the design of an innovative, AI-powered
user interface based on human factors methodology to support
the patient’s cognition, enhance the ability to comprehend
medication information, and ultimately improve medication
adherence. The aims are listed below:
1. Aim 1: identify barriers to medication information
comprehension.
2. Aim 2: iteratively design and evaluate the AI-powered
medication information visualization interface.
3. Aim 3: test the prototype for better comprehension and
adherence to medication information.
JMIR Res Protoc 2020 | vol. 9 | iss. 11 | e21659 | p. 2http://www.researchprotocols.org/2020/11/e21659/
(page number not for citation purposes)





We will use RxNorm and the Unified Medical Language System
to design the AI infrastructure to unify medication and
biomedical terminologies systematically. Generic medication
names for the most prescribed and commonly used oral
medications will be obtained from RxNorm. A recursive neural
network (RNN)–based methodology was used for developing
the AI-based algorithm. Artificial neural networks (ANNs) are
modeled after the human brain and structured to recognize and
recall information. An RNN is a type of ANN algorithm that
operates on structured inputs of an acyclic graph. It is a type of
architecture used in machine learning for various applications,
such as predicting the weather, processing images, and language
composition. We implemented this architecture and used deep
learning algorithms using Amazon SageMaker for integrating
the AI aspects into the smartphone app. We will use AI to
monitor features of user analytics, use predictive tools to
understand user interaction, and create a dynamic user
environment of the app that changes based on the user’s previous
input. The deep learning methodology of RNNs will guide us
to develop such features. The user’s input will be reused to train
the machine learning model.
Aim 1: Identify Barriers to Medication Information
Comprehension
Methods Overview
We will conduct a mixed methods study following these three
steps:
1. Step 1: identify patients’ perceptions of fear and biases
regarding medication information from a focus group study.
2. Step 2: the eye-tracking study will provide design
configurations for the interface.
3. Step 3: psychological refractory period (PRP) will help us
understand functionalities based on user profile variations.
Step 1: Observational Study
In the first phase, we will conduct multiple group interviews
(ie, focus group methodology) for patients to interact to gain
new knowledge and generate meaningful suggestions, opinions,
and feedback [27]. Each focus group will have 5 patients. We
will ask each patient to provide us with the name of a new
medication, and we will print the Medication Guide per FDA
to facilitate discussions. The study measures are (1) specific
medication information on the leaflet that is hard to comprehend,
(2) trigger points for information avoidance and perceived
familiarity, and (3) patients’ suggestions. An initial coding
framework will be developed by two coders to establish themes
and subthemes from the transcript data. Refinement of coding
will follow, and any disagreement between two coders will be
resolved by consulting with a third coder.
Step 2: Eye-Tracking Study
In the second phase, we will design a web-based mock interface
representing medication information in an interactive
visualization format. We will use medication information from
the FDA’s Medication Guides that are provided to patients for
designing this mock-up. We will use the open-source software
platform Pupil, a wearable, mobile, eye-tracking headset with
one scene camera and one infrared-spectrum eye camera for
dark pupil detection [28]. The video streams are read using
Pupil capture software for real-time pupil detection, gaze
mapping, recording, and other functions. We will use a mobile
platform to display this information. Patients will be asked to
wear the Pupil device and browse the web-based mock-up of
medication information on a mobile device. They also will be
asked to perform a series of tasks; for example, “find the most
common side effect of the drug,” “find the storage instructions,”
“find instructions on whether you can break the pill in half and
take it,” etc. Patients will be asked to browse the interface data
and provide overall feedback in a short semistructured verbal
interview that will follow the task segment. The study measures
are (1) specific areas in medication information where attention
is focused, (2) real-time gaze movement using the Pupil software
algorithm, and (3) accuracy, response time, and eye-movement
data. For the data analysis, the Gaze History Length option for
each surface decides how many recent gaze positions will be
used to calculate the heat map based on gaze history. We will
use annotation software to label timestamps of specific video
gazing to understand the attention locus. Two researchers will
assess the transcribed audio interviews to generate trigger points,
user-centered design recommendations, and user preferences.
Step 3: Psychological Refractory Period Paradigm Study
In the third phase, we seek to understand users’ variations in
their ability to complete two tasks in rapid succession for a
goal-directed behavior; in our proposed research design, this
understanding will be unpacked by determining the limits of
dual-tasking by self-regulation and task-based measurement.
The specific methodology for data collection is the PRP task,
a tool provided by the National Institutes of Health Science of
Behavior Change (SOBC) program [29-31]. The PRP gives
specific instructions, which participants must follow as stated
on the screen. The time, variation, and accuracy are measured
through PRP and results are readily available to be downloaded
after the session. The results will help us understand
functionalities based on user profile variations, including age,
health literacy, or any other physical and mental conditions.
Patients will be given the test from the SOBC site from a web
browser on a laptop computer. The study measures are (1)
response time and (2) task-switching time. For the data analysis,
we will note the variations of the response time based on
patients’ ages and backgrounds to help create design features
of buttons and clickable interface functional requirements in
the design for the interface.
Study Subjects and Recruitment Methods
We will recruit 50 patients from our outpatient clinic sites. A
research assistant will conduct a telephone interview for
cognitive status to ensure potential participants meet the
minimum cutoff score of 34 during cognitive screening based
on TICS-M test for sound cognitive status and health literacy
level [32]. Participants will come to our main site at a lab at the
Western University of Health Sciences, Pomona, California.
Inclusion criteria will be patients who are aged 18-65 years and
have started at least one new medication to develop visualization
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information. The observational study (30 minutes), eye-tracking
study (20 minutes), and PRP (10 minutes) will take around one
hour, including instructions and filling out consent forms.
Patients will be offered a US $100 gift card and access to a
pharmacist consultation for the duration of the study.
Data Collection
We propose to collect the following data: (1) observation notes
and audio recordings, (2) video data from Pupil on specific
locations on gaze mapping, surface detection, and audio
streaming data, (3) notes from user observations and audio of
the short interviews after the eye-tracking study, and (4)
task-switching and task-processing time from PRP.
Sample Size Justifications
Previous observation and eye-tracking studies used 10-90
participants and 5-40 participants, respectively [17,33,34]. We
plan to recruit 50 patients for this aim.
Limitations
Patients may experience peer pressure to show conformity to
medication information. We will have the moderator clarify to
patients that the questions have no right or wrong answers. Some
errors may result from gaze mapping, surface detection, and
algorithm data. Therefore, we will calibrate the software and
hardware before each study.
Aim 2: Iteratively Design and Evaluate the
AI-Powered, Medication Information Visualization
Interface
Methods Overview
We will use an AI-based smartphone interface platform for our
iterative design of the medication information interface. To
develop such a platform, we will use the Amazon SageMaker
engine for creating an AI-powered interface with our
RNN-based algorithm. This interface will be able to take into
account users’ interactions and translate the data into a data
analytics–based back-end server. This prototype will be
developed in Java and Python languages for both android and
iOS platforms.
Human Factor–Based Iterative Design
We will use a human factor–based methodology to iteratively
design the app from the functional requirements from Aim 1
using user-centered design principles [12,23,34]. We will use
the usability inquiry approach for the iterative design to
understand the users’ likes, dislikes, and needs [35,36]. The
multidisciplinary research team, including 20 clinicians with
diverse clinical backgrounds and 12 researchers, will then
iteratively review and revise the app based on the written and
verbal feedback related to the usability (ie, think-aloud
methods), efficiency, and ease of use for 4 months or until no
further revisions are identified. App usability will not be
measured remotely. A research assistant will recruit clinicians
and other team members for the iterative design process related
to the front end of the prototype app. We will ask users to
interact with the mock-up in the mobile interface and provide
them with tasks using think-aloud methods. Think-aloud
methods will provide rich verbal data about specific changes
and functionalities of the initial mock-up [35,37]. We will audio
record and screen record sessions, using Camtasia (TechSmith
Corporation), to analyze verbal feedback from the think-aloud
method and measure the mouse movements. We will analyze
the data from the think-aloud sessions and screen recordings to
identify design functionalities, and we will change the design
based on feedback. The think-aloud sessions and screen
recordings will provide us with specific user comments and
interface design preferences. Our design team will incorporate
those changes and take users’ feedback in an iterative process
unless a final design agreement has been reached.
Contextual Medication Information for the Visualization
Two medication information expert pharmacists will develop
contextual medication information—10 pieces of crucial
information—that the patients should know [38]. This
information may include indications for use, essential warnings,
contraindications, storage information, typical side effects, and
directions for use. We will use this information in the design
of the visualization as well as use just the text version of the
information as an intervention for Aim 3.
Usability Testing of the App
Two usability surveys will be emailed to users. The first survey
instrument, which has been validated and created from the
research on smartphone apps from the industry, is specifically
designed for mobile interface design [39,40]. This Likert
scale–based survey is based on a heuristic evaluation for easy,
quick, and reliable assessment of the mobile user interface
design [39]. The second survey instrument is the hierarchical
task measure developed by the SOBC program. Hierarchical
task analysis helps us to understand how users categorize tasks
in hierarchical steps in their minds [41]. The hierarchical
reinforcement learning task measures participants’ abilities to
discover and use higher-order structures in their environment.
Participants are presented with 18 stimuli composed of three
dimensions: shape, orientation, and border color. The task
requires that participants respond to stimuli by pressing one of
three keys in response to each of the stimuli. In a “flat”
condition, the keys are randomly associated with the shapes so
that the participant must learn each association independently.
We will iteratively change the design of the visualization based
on the survey results.
Study Subjects and Recruitment Methods
We will recruit patients (18-65 years of age) at clinic sites during
the discharge process with access to, and the ability to use, a
smartphone device. A research assistant will conduct the
modified Telephone Interview for Cognitive Status (TICS-M)
test for cognitive status to ensure potential participants meet
the inclusion criteria of a minimum cutoff score of 34 for sound
cognitive status and health literacy level [32]. Patients will be
given a US $50 gift card for participation. We will load our
medication information tool remotely into the users’ app and
send out an e-survey for ratings and feedback. The data from
the usability surveys will be sent to a HIPPA (Health Insurance
Portability and Accountability Act)-protected secured server.
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For the hierarchical task, the results will be shown in graphs
with the percentage of error of participants’ abilities to simplify
tasks. We will correlate the means of the graphs with the results
from the survey instruments for a personalized design.
Sample Size Justifications
Previous studies have included usability surveys with 96-404
participants [40,41]. We plan to recruit 300 patients from our
outpatient clinics at the Western University of Health Sciences.
Limitations
We may receive numerous users’ input about the interface. The
research team will apply only the changes that correspond to
the current literature of design conforming to patient safety [42].
Aim 3: Test the Prototype for Better Comprehension
and Adherence to Medication Information
Our hypothesis for this aim is that the AI-powered visualization
tool in the app improves medication information comprehension
and adherence when compared with written medication
information and contextual plain-text information.
Study Design
The study has a single-blind and sequentially randomized design.
The full design of the study will include two arms with 2
(modality: app versus app with text) × 2 (format: an app with
visualization versus an app with contextual medication text
information) × 2 (context: contextual medication information
versus information without context) + 1 (control: app) design.
The design is depicted in Figure 1. The randomized trial using
binary options (yes or no) provides the stratification needed to
identify groups that are prone to get benefits from the different
presentations of medication information. The results from the
sequential randomized design will help us detect statistically
significant differences using a larger sample size. The first
randomization helps with filtering patients who have better
information recall regardless of the app. The second
randomization helps with finding the actual effects of the tool
when compared with different interventions.
Figure 1. Study design. The participants are randomized first at R: one group uses only the app (A) and another group is given the app with medication
information text (AT). At time point 1 (T1), after 4 weeks, both groups are evaluated for information recall (>80%). Then, after a second randomization
(R), the participants are divided into the following groups: app with medication information text (AT), app with contextual medication information text
(ACT), and app with visualization (AV). T0: baseline; T2: time point 2 (after 12 weeks).
Intervention
The study will include three intervention conditions loaded into
the smartphone app platform. We can better compare the effects
of the medication information visualization tool by comparing
the outcomes of these three interventions to understand the
impacts of our visualization. In the first condition, the app with
medication information text (AT), the medication text
information will be loaded into the app platform. This
medication text is the Medication Guide, which is approved by
the FDA. In the second condition, the app with contextual
medication information text (ACT) is shown as a printed-text
version. This contextual information (ie, 10 pieces of crucial
information patients should know) that we included in our
visualization will be shown only as the text version in this
intervention. In the third condition, an app with visualization
(AV), the interactive app will be loaded with our medication
information visualization tool, including the visual format of
the contextual information.
Study Subjects and Recruitment Methods
We will recruit patients (18-65 years of age) from our clinics.
Inclusion criteria will include participants who have access to
a smartphone, can provide their consent, do not have any
cognitive impairment, and who have at least two medications
on profile for which we have created a visualization. At the time
of recruitment, we will ensure that the patients meet the
minimum cutoff score of 34 during cognitive screening using
the TICS-M test and health literacy level [32]. Eligible patients
will be allocated in a 1:1 ratio to the two arms of the study
according to a computer-generated random sequence stratified
by third-party software.
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In the first randomization, patients will be randomized into two
groups at baseline. The control group (ie, the app-only [A]
group) will have the smartphone app with no visualization, and
the intervention group will have the app with text information
only as in the current Medication Guide (AT) [43]. At 4 weeks,
patients from both the control and intervention groups from
both arms, who have scores of 80% or higher in the information
recall survey, will continue in the study with the same
intervention, in either the A or AT group. Those who do not
meet the performance cutoff will be rerandomized further into
two groups for each arm. In the second randomization at 4
weeks, the control group from the first arm (A) will have the
smartphone app with just text information about medication
(AT), and the intervention group will have the smartphone app
with the prototype of medication information visualization (AV).
The control group from the second arm (AT) will have the app
with contextual medication information in a text format (ACT),
and the intervention group will have the app with our
visualization design (AV). This part of the study will continue
for 8 weeks. The monitoring is not a continuous process. Only
the principal investigator will have access to the main file and
will check the adherence and patient analytics at 4 and 8 weeks.
Survey Tools
Three survey measures will be used. The first survey will be
used to understand information recall; we will design a timed
questionnaire, with true or false responses, for each medication
in a patient’s regimen that includes the 10 pieces of crucial
medication information we embedded into the visualization
interface. Each patient will be tested on different medications
at 4 and 12 weeks to show understanding and knowledge. For
example, if a patient takes simvastatin, metformin, and losartan,
only those specific medication-related questions will be asked.
The second survey will help us to understand the patient’s
perception of medication knowledge. We will use a validated
survey instrument to assess patients’ attitudes, confidence, and
perceived medication knowledge [44]. This instrument was
validated with high internal consistency (Cronbach α=.833).
The third survey will use the 8-item Morisky Medication
Adherence Scale (MMAS-8). The MMAS-8, whose scores range
from 0 to 8 with lower scores indicating lower adherence, is a
widely used tool for self-reported medication adherence; the
scale was found to be reliable and significantly associated with
adherence control (P<.05), with 93% sensitivity as well as 53%
specificity for low adherence in a validation study [37].
Data Collection
We will collect demographics data at baseline. Data will be
collected at 4 and 12 weeks. The 12-week time point will be
considered the primary endpoint for the study. The AI platform
on the smartphone app’s back end will provide patient analytics
on the usage of the mobile app (ie, intake of medications in the
app diary and access frequencies).
Study Measures
The following study measures will be conducted:
1. Medication information comprehension from the first survey
(primary outcome) [45]; the comprehension measure will
be a composite of three subscales:
a. Relevance to understanding patients’ attitudes,
b. Patients’ levels of confidence and knowledge of
medication use, measured using a Likert scale, and
c. Information recall subscale, measured using a
dichotomous scale (ie, true or false).
2. Survey on patients’perceptions of medication information.
3. Medication adherence (secondary outcome) will be
operationalized by the following:
a. MMAS-8 [46] survey score; the dichotomous response
categories are yes or no for each item, and
b. Analytics of the patients’ daily intake of medications
diary from the smartphone app.
Data Analysis
Demographic information will be presented using descriptive
statistics. We will analyze the groups using t tests to detect
differences between the means for continuous data. Chi-square
analysis will be used to evaluate differences between arms for
primary and secondary outcomes. We will use the univariate
analysis of variance to calculate the mean differences between
groups. If the distribution is not normal, we will use general
linear modeling for the data analysis [47,48]. The AI-based
analytics data from the smartphone will show us the patients'
medication intake and we will correlate that score with our
interventions.
Sample Size Justifications
To detect a 1-point improvement on the Likert scale and 80%
power at the 5% significance level, the study would require 100
subjects in each group with 1:1 allocation for the second
randomization (ie, AT: AV and ACT: AV). To allow for an
11% loss due to dropouts and those lost to follow-up, we would
need to recruit 888 patients, allowing up to 50% of the patients
to move to the second randomization following the first
randomization with a score of 80% or higher in the medication
recall questionnaire survey with assigned intervention.
Recruitment of 888 patients is also sufficient to detect a 1-point
improvement on the MMAS-8 (the secondary outcome), with
80% power at 5% significance. Therefore, our target is to recruit
900 patients.
Limitations
We expect to enroll a large number of patients for this sequential
randomized design. We do not anticipate significant problems
because our clinics are excellent sites for recruitment. The
recruiting advantage is due to the academic affiliations with
faculty and residents. However, given our large sample size
requirements, to the extent that we cannot recruit around 888
patients, our study will lack rigor.
Results
We will conduct preliminary data collection for the studies in
2021. Results are expected to be published in 2022.
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This protocol addresses the problem of creating an AI-powered
smartphone app to engage and predict user analytics. This
unique idea builds upon an understanding of how users interact
with complex medication task information and interactively
visualize crucial medication information that frequently is
ignored. Previous studies have also successfully shown that
informatics platforms have the potential to empower patients
[49]. While AI-based algorithms have been used in predicting
health outcomes [20,50], very few studies have looked into the
user's interaction analytics and ways to build better visualization
techniques to engage the user [51-54]. This protocol focuses on
creating uniform data standards that are crucial for efficient
health information exchange [55]. This protocol provides future
researchers and visualization designers with a new and
innovative way to design and improve health care smartphone
apps.
Conclusions
This study will lead the future of innovative AI-powered
smartphone app design and act as the aid to improve medication
risk comprehension, which may ultimately improve medication
adherence. The results from this study also open up future
research opportunities to understand how patients manage
complex medication information and will inform the format
and design for innovative AI-powered digital interfaces for
Medication Guides.
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ACT: app with contextual medication information text
AI: artificial intelligence
ANN: artificial neural network
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AT: app with medication information text
AV: app with visualization
FDA: US Food and Drug Administration
HIPPA: Health Insurance Portability and Accountability Act
MMAS-8: 8-item Morisky Medication Adherence Scale
PRP: psychological refractory period
RNN: recursive neural network
SOBC: Science of Behavior Change
TICS-M: modified Telephone Interview for Cognitive Status
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